The Intravascular Generation of Fibrinogen Derivatives and the Blood Vessel Wall in Venous Thrombosis and Disseminated Intravascular Coagulation

Summary

Both deep venous thrombosis and DIC are intermediate mechanisms of disease – both are a consequence of the deposition of fibrin-rich material in blood vessels some distance from the primary site of tissue destruction. The great difference in the sites of fibrin deposition may depend on the extent and site of activation of the clotting mechanism. DIC likely occurs in the fluid phase of the blood as a consequence of massive fibrin formation while thrombosis results from limited fibrin formation at the interface between blood and vessel wall. Leukocytes may be essential for attaching thrombi to the vessel wall in many places.

• References

• 1 Alkjaersig N, Abe T, Seegers W. H. 1955; Purification and quantitative determination of platelet factor 3. American Journal of Physiology 181: 304.
• 2 Altman R, Hemker H. C. 1967; Contact activation in the extrinsic blood clotting system. Thrombosis et Diathesis Haemorrhagica 18: 525.
• 3 Amundsen M. A, Spittell J. A, Thompson J. A, Owen Jr. C. A. 1963; Hypercoagulability associated with malignant disease and with the postoperative state. Evidence for elevated levels of antihomophilic globulin. Annals of Internal Medicine 58: 608.
• 4 Astrup T. 1969. Relation between fibrin formation and fibrinolysis. In: Thrombosis. (eds.) Sherry S, Brinkhous K. M, Genton E, Stengle J. M. National Academy of Sciences; Washington, D. C; 609.
• 5 Austen K. F. 1974; Hageman factor-dependent coagulation, fibrinolysis and kinin generation. Transplantation Proceedings 6: 39.
• 6 Bach C, Lewis G. P. 1974; Lymph flow and lymph protein concentration in the skin and muscle of the rabbit hind limb. Journal of Physiology (London) 235: 477.
• 7 Bagdasarian A, Lahiri B, Colman R. W. 1973; Origin of the high molecular weight activations of human plasmin kallikrein. Journal of Biological Chemistry 248: 7742.
• 8 Banerjee R. N, Sahni A. L, Kumar V, Arya M. 1974; Antithrombin III deficiency in maturity onset diabetes mellitus and atherosclerosis. Thrombosis et Diathesis Haemorrhagica 31: 339.
• 9 Baumann K, Straub P. W. 1969; Congenital deficiency of Hageman factor (clotting, factor XII). Report on the first two families found in Switzerland. Helvetica Medica Acta 34: 313.
• 10 Bell W. R, Regoecz E. 1970; Isotopic studies of therapeutic anticoagulation with a coagulating enzyme. Journal of Clinical Investigation 49: 1872.
• 11 Bouma B. N, Griffin J. H. 1977; Human prekallikrein (plasminogen proactivation): Purification, characterization and activation by activated factor XII. Thrombosis and Haemostasis 38: 136.
• 12 Boyden S. 1962; The chemotactic effect of mixtures of antibody and antigen on polymorphonuclear leukocytes. Journal of Experimental Medicine 115: 453.
• 13 Boyles S, Lewis G. P, Westcott B. 1970; Changes in the composition of hind limb lymph after chemical injury. British Journal of Pharmacology 39: 798.
• 14 Brakman P. 1966; The fibrinolytic system in human blood during pregnancy. American Journal of Obstetrics and Gynecology 94: 14.
• 15 Brakman P, Albrechtsen O. K, Astrep T. 1967; Blood coagulation, fibrinolysis and contraceptive hormones. Journal of American Medical Association 199: 69.
• 16 Brinkhous K. M, Smith H. P, Warner E. D, Seegers W. H. 1939; Inhibition of blood clotting: unidentified substance which acts in conjunction with heparin to prevent conversion of prothrombin into thrombin. American Journal of Physiology 125: 683.
• 17 Buckley I. K, Ryan G. B. 1969; Increased vascular permeability: The effect of histamine and serotonin on rat mesenteric blood vessels in vivo. American Journal of Pathology 55: 329.
• 18 Burrowes C. E, Habal F. M, Movat H. Z. 1975; The inhibition of human plasma kallikrein by antithrombin III. Thrombosis Research 7: 175.
• 19 Burrowes C. E, Movat H. Z, Soltay H. J. 1971; The kinin system of human plasma VI. The action of plasmin. Proceedings of the Society for Experimental Biology and Medicine 138: 959.
• 20 Bywaters E. G. L, Beall D. 1941; Crush injuries with impairment of renal function. British Medical Journal 1: 425.
• 21 Cash J. D. 1975; Short-term enhancement of plasminogen activator in vivo by drugs. Thrombosis et Diathesis Haemorrhagica 34: 648.
• 22 Cash J. D, McGill R. C. 1969; Fibrinolytic response to moderate exercise in young male diabetics and non-diabetics. Journal of Clinical Pathology 22: 32.
• 23 Clarke R. L, Orandi A, Cliffton E. E. 1960; Induction of fibrinolysis by venous obstruction. Angiology 11: 367.
• 24 Cochrane C. G, Revak S. D, Akin B. S, Wuepper K. D. 1972. The structural characteristics and activation of Hageman factor. In: Inflammation, Mechanism and Control. (eds.) Lepow I. H, Ward P. A. Academic Press; New York and London: 119.
• 25 Cochrane C. G, Revak S. D, Wuepper K. D. 1973; Activation of Hageman factor in solid and fluid phases. Journal of Experimental Medicine 138: 1564.
• 26 Cochrane C. G, Wuepper K. D. 1971; First component of the kinin – forming system in human and rabbit plasma: Its relationship to clotting factor XII (Hageman factor). Journal of Experimental Medicine 134: 989.
• 27 Collen D, Decock F, Verstraete M. 1975; Immunochemical distinction between antiplasmin and α₁-antitrypsin. Thrombosis Research 7: 245.
• 28 Collins G. J, Haymann R. L, Zaitchuk R. 1975; Hypercoagulability in patients with peripheral vascular disease. American Journal of Surgery 130: 2.
• 29 Colman R. W. 1969; Activation of plasminogen by human plasma kallikrein. Biochemical and Biophysical Research Communication 35: 273.
• 30 Colman R. W. 1974; Formation of human plasma kinin. New England Journal of Medicine 291: 509.
• 31 Colman R. W, Bagdasarim A, Talamo R. C, Scott C. F, Seavey M, Guimaraes J. A, Pierce J. V, Kaplan A. P. 1975; Wilhams trait. Human kinogen deficiency with diminished levels of plasminogen proactivator and prekallikrein associated with abnormalities of the Hageman factor-dependent pathways. Journal of Clinical Investigation 56: 1650.
• 32 Cooke E. D, Bowcock S. A, Plicher M. F, Ibbotson R. M, Gordon Y. B, Sola C. M, Chard T, Ainsworth M. E. 1975; Serum fibrin(ogen) degradation products in diagnosis of deep vein thrombosis and pulmonary embolism after hip surgery. Lancet July 12: 51.
• 33 Cooper H. A, Bowie E. J. W, Owen Jr. C. A. 1973; Chronic induced intravascular coagulation in dogs. American Journal of Physiology 225: 1355.
• 34 Cooperberg A. A, Teitelbaum J. I. 1961; The concentration of antihemophilic globulin (AHG) in patients with coronary artery disease. Annals of Internal Medicine 54: 899.
• 35 Cope O, Moore F. D. 1943; The study of capillary permeability in experimental burns and burn shock using radioactive dyes in blood and lymph. Journal of Clinical Investigation 23: 241.
• 36 Davidson E, Tomlin S. 1963; The levels of the plasma coagulation factors after trauma and childbirth. Journal of Clinical Pathology 16: 112.
• 37 Dunn J. S, Gillepsie M, Niven J. S. F. 1941; Renal lesions in two cases of crush syndrome. Lancet 241: 549.
• 38 Flute P. T, Kakkar V. V, Renney J. T. G, Nicolaides A. N. The blood and venous thromboembolism. In: Thromboembolism: Diagnosis and Treatment. (eds.) Kakkar V. V, Joucher A. J. The Wilhams and Wilkins Co.; Baltimore, Maryland: 1972: 2-12.
• 39 Forbus W. D. 1952. In: Reaction to Injury. The Wilhams and Wilkins Co.; Baltimore, Maryland: 61.
• 40 Fulton L. D, Page E. W. 1948; Nature of the refractory state following sublethal dose of human placental thromboplastin. Proceedings of the Society for Experimental Biology and Medicine 68: 594.
• 41 Gallus A. S, Hirsh J, Gent M. 1973; Relevance of preoperative and postoperative blood tests to postoperative leg — vein thrombosis. Lancet II: 325.
• 42 Gigli I, Mason J. W, Colman R. W, Austen K. F. Interaction of plasma kallikrein with CT inhibitor. Journal of Immunology 104: 574.
• 43 Gjønnaess H. 1972; Cold – promoted activation of factor VII. Relation to the coagulation system. Thrombosis et Diathesis Haemorrhagica 28: 194.
• 44 Godal H. C, Madsen K, Weissen-Meyer R. 1962; Thromboembolism in patients with total proconvertin (factor VII) deficiency. Acta Medica 171: 325.
• 45 Goodnight Jr. S. H. 1974; Bleeding and intravascular clotting in malignancy: a review. Annals of New York Academy of Science 230: 271.
• 46 Goodnight S. H, Kenoyer G, Rapaport S. I, Patch M. J, Lee J. A, Kurze T. 1974; Defibrination after brain – tissue destruction. A serious complication of head injury. New England Journal of Medicine 290: 1043.
• 47 Grant L. 1973. The sticking and emigration of white blood cells in inflammation. In: The Inflammatory Process. Academic Press; New York and London: 205.
• 48 Gurewich V, Hutchinson E. 1971; Detection of intravascular coagulation by a serial-dilution protamine sulfate test. Annals of Internal Medicine 75: 895.
• 49 Haddy F. J, Scott J. B, Grega G. J. 1972; Effects of histamine on lymph protein concentration and flow in the dog fore limb. American Journal of Physiology 223: 1172.
• 50 Harpel P, Bang N. U, Homburger F, Treger A. 1966; Plasminogen activator in mouse uterine fluid: Its suppresion by estradiol and progesterone. Proceedings of the Society for Experimental Biology and Medicine 22: 1192.
• 51 Harpel P. C, Mosesson M. W. 1973; Degradation of human fibrinogen by plasma α₂-macroglobulin-enzyme complexes. Journal of Clinical Investigation 52: 2175.
• 52 Hathaway W. E, Belhasen L. P, Hathaway H. S. 1965; Evidence for a new plasma thromboplastin factor I. Case report, coagulation studies and physicochemical properties. Blood 26: 521.
• 53 Hawiger J, Niewiarowski S, Gurewich V, Thomas D. P. 1970; Measurement of fibrinogen and fibrin degradation products in serum by staphylococcal clumping test. Journal of Laboratory Clinical Medicine 75: 93.
• 54 Haynes F. 1932; Factors which influence the flow and protein content of subcutaneous lymph in the dog. II. The effect of certain substances which alter the capillary circulation. Journal of Physiology (London) 101: 612.
• 55 Herold R, Straub P. W. 1973; In vivo role of factor XII (Hageman factor) in hypercoagulability and fibrinolysis. Journal of Laboratory Clinical Medicine 79: 397.
• 56 Highsmith R. F, Rosenberg R. D. 1974; The inhibition of human plasmin by antithrombin-heparin cofactor. Journal of Biology and Chemistry 249: 4335.
• 57 Hume M, Chan Y.-K. 1969. Discrimination between normals and patients with venous thrombosis based on blood tests. In: Thrombosis. (eds.) Sherry S, Genton E, Stengle J. M. National Academy of Sciences; Washington, D. C.: 566.
• 58 Hume M, Sevitt S, Thomas D. P. 1970. Mechanisms of venous thrombosis. In: Venous Thrombosis and Pulmonary Embolism. Harvard University Press; Cambridge, Mass.: 58.
• 59 Jofee S. N. 1975; The incidence of postoperative deep vein thrombosis. Thrombosis Research 7: 141.
• 60 Johnson J. F, Seegers W. H, Braden R. G. 1952; Plasma Acglobulin changes in placenta abruption. American Journal of Clinical Pathology 22: 322.
• 61 Kalousek F, Konigsberg W, Nemerson Y. 1975; Activation of factor IX by activated factor X: A link between the extrinsic and intrinsic coagulation systems. FEBS Letters 50: 382.
• 62 Kaplan A. P, Austen K. F. 1971; Prealbumin activator of prekallikrein. II. Derivation of activators of prekallikrein from active Hageman factor digestion with plasmin. Journal of Experimental Medicine 133: 696.
• 63 Kaplan A. P, Austen K. F. 1972; a The fibrinolytic pathway of human plasma. Isolation and characterization of the plasminogen proactivation. Journal of Experimental Medicine 136: 1378.
• 64 Kaplan A. P, Kay A. B, Austen K. F. 1972; b A prealbumin activator of kallikrein. III. Appearance of chemotactic activity for human neutrophils by the conversion of human prekallikrein to kallikrein. Journal of Experimental Medicine 135: 81.
• 65 Keller H. N, Sorkin E. 1968; Chemostaxis of leukocytes. Experientia 24: 641.
• 66 Kwaan H. C, Lo R, McFadzean A. J. S. 1957; On the production of plasma fibrinolytic activity within veins. Clinical Sciences 16: 241.
• 67 Laake K, Osterud B. 1974; Activation of purified plasma factor VII by human plasmin, plasma kallikrein, and activated components of the human intrinsic blood coagulation system. Thrombosis Research 5: 759.
• 68 Lahiri B, Talamo R. C, Mitchell B, Bagdasarían A, Colman R. W, Rusenberg R. 1976; Antithrombin III, an inhibitor of plasma kallikrein. Archives of Biochemistry and Biophysics 175: 137.
• 69 Landerman N. S, Webster M. E, Becker E. L, Ratcliffe H. D. 1962; Heriditary angioneurotic edema. Journal of Allergy 33: 330.
• 70 Lasch H. G, Heene D. L, Huth K, Sandritter W. 1967; Pathophysiology clinical manifestations and therapy of consumption – coagulopathy (Verbrauchs-Koagulopathie). American Journal of Cardiology 20: 381.
• 71 Leary O. C, Hertig A. T. 1950; The pathogenesis of amniotic-fluid embolism. I. Possible placental factors — aberrant squamous cells in placentas. New England Journal of Medicine 243: 588.
• 72 Leavey R. A, Kahn S. B, Brodsky I. 1970; Disseminated intravascular coagulation, a complication of chemotherapy in acute myelomonocytic leukemia. Cancer 26: 142.
• 73 Lewis G. P. 1967; Intracellular enzymes in local lymph as a measure of cellular injury. Journal of Physiology (London) 191: 591.
• 74 Lewis G. P. 1969; Changes in composition of rabbit hind limb lymph after injury. Journal of Physiology (London) 205: 619.
• 75 Lewis G. P. 1975; A lymphatic approach to tissue injury. New England Journal of Medicine 293: 287.
• 76 Lewis G. P, Wawretschek W. A. 1971; Effect of thermal injury on the kinin system in rabbit hind limb lymph. British Journal of Pharmacology 43: 127.
• 77 Lewis G. P, Winsey N. J. P. 1970; The action of pharmacologically active substances on the flow and composition of cat hind limb lymph. British Journal of Pharmacology 40: 446.
• 78 Liban E, Raz S. 1966; A clinicopathologic study of fourteen cases of amniotic fluid embolism. American Journal of Clinical Pathology 51: 477.
• 79 Liu C. T. 1971; Traumatic shock: Evidence for chemical release from traumatized tissue in dogs. Aerospace Medicine 42: 403.
• 80 Loosli C. G, Baker R. F. 1963; Acute experimental pneumococcal (Type I) pneumonia in the mouse: The migration of leukocytes from the pulmonary capillaries into the alveolar spaces as revealed by the electron microscope. Transactions of American Clinical Climatologic Association 74: 15.
• 81 Lorentsen E, Eika C, Godal H. C. 1974; Coagulation studies in chronically bedridden patients. Acta Medica Scandinavia 195: 79.
• 82 MacFArlane R. G, Biggs R. 1946; Observations on fibrinolysis. Spontaneous activity associated with surgical operations, trauma, etc. Lancet II: 862.
• 83 Majno G, Palade G. E, Schoetl G. I. 1961; Studies on inflammation. II. The site of action of histamine and serotonin along the vascular tree: A topographic study. Journal of Biophysical and Biochemical Cytology 11: 607.
• 84 Mandle R, Kaplan A. P. 1977 Hageman factor substrates. II. Human plasma prekallikrein. Mechanism of activation by Hageman factor and participation on Hageman factor proteolysis. Journal of Biological Chemistry. in press.
• 85 Marciniak E, Farley C. H, DeSimone P. A. 1974; Familial thrombosis due to antithrombin III deficiency. Blood 43: 219.
• 86 Marcus A. J, Zucker-Franklin D. 1964; Studies on subcellular platelet particles. Blood 23: 389.
• 87 Margolis J. 1958; Activation of plasma by contact with glass: Evidence for a common reaction which releases plasma kinin and initiates coagulation. Journal of Physiology 144: 1.
• 88 Marshall R, Esnouf M. P. 1968; The effect of Ancistrodon rhodostoma venom in the dog. Clinical Sciences 35: 251.
• 89 Mayon-White R, Solandt O. M. 1941; A case of limb compression ending in uraemia. British Medical Journal 1: 434.
• 90 McCarell T. D, Drinker C. K. 1941; Cervical lymph production during histamine shock in the dog. American Journal of Pathology 133: 64.
• 91 McConnell D. J, Loeb J. N. 1974; Kallikrein inhibitory capacity of α₁-macroglobulin subunits. Proceedings of the Society for Experimental Biology and Medicine 147: 891.
• 92 McKay D. G. 1965. In: Disseminated Intravascular Coagulation. An Intermediary Mechanism of Disease. Hoeber Medical Division, Harper and Roe; Newfork, Evanston and London: 359.
• 93 McKay D. G, Muller-Berghaus G. 1967; Therapeutic implications of disseminated intravascular coagulation. American Journal of Cardiology 20: 392.
• 94 McKay D. G, Shapiro S. S. 1958; Alterations in the blood coagulation system induced by bacterial endotoxin. I. In vivo (generalized Shwartzman reaction). Journal of Experimental Medicine 107: 353.
• 95 McKenzie R, Pepper D. S, Kay A. B. 1975; The generation of chemotactic activity for human leukocytes by the action of plasmin on human fibrinogen. Thrombosis Research 6: 1.
• 96 Menton I. S, White R. W. B, Smith P. A, Dewar H. A. 1967; Diurinal variation of fibrinolytic activity and plasma-11-hydroxycorticosteroid levels. Lancet II: 531.
• 97 Mersky C, Johnson A. J, Kleiner G. J, Wohl H. 1967; The defibrination syndrome: clinical features and laboratory diagnosis. British Journal of Haematology 13: 528.
• 98 Mersky G, Kleiner G. J, Johnson A. J. 1966; Quantitative estimation of split products of fibrinogen in human serum, relation to diagnosis and treatment. Blood 28: 1.
• 99 Minna J. D, Robboy S. J, Colman R. W. 1974. In: Disseminated Intravascular Coagulation in Man. Charles C. Thomas; Springfield, Ill.: 3.
• 100 Mortiz A. R, Adelson L. 1971. Physical agents in causation of injury and disease. In: Pathology. (ed.) Anderson W. A. D. The C. V. Mosby Co.; St. Louis: 152.
• 101 Mylon E, Winternitz M. D. 1946; The differentiation of potassium from other agents associated with the toxic effects of tourniquet shock. American Journal of Physiology 146: 254.
• 102 Nemerson Y. 1976; Biological control of factor VII. Thrombosis and Haemostasis 35: 96.
• 103 Nemerson Y, Pitlick F. A. 1970; Purification and characterization of the protein component of tissue factor. Biochemistry 9: 5100.
• 104 Netsky M. G, Leiter S. S. 1943; Capillary permeability to horse protein in burn shock. American Journal of Physiology 140: 1.
• 105 Nicolaides A. N, Gordon-Smith I. 1975. In: Thromboembolism: Aetiology, Advances inprevention and Management. A rational approach to prevention. Medical and Technical Publishing Co. Ltd.; Lancester: 205.
• 106 Nicolaides A. N, Kakkar V. V, Field E. S, Renney J. T. G. 1971; The origin of deep vein thrombosis: a venographic study. British Journal of Radiology 44: 653.
• 107 Niewiarowski S. 1973. Detection of fibrinogen derivatives in plasma and in serum and its significance in the diagnosis of intravascular coagulation and fibrinolysis. In: French Congress of Anaestheology. (Symposium on Fibrinolysis and Defibrination). Librairie Arnett; Paris: 67.
• 108 Niewiarowski S, Bankowski E, Rogowicka R. 1965; Studies on the adsorption and activation of the Hageman factor (factor XII) by collagen and elastin. Thrombosis et Diathesis Haemorrhagica 14: 387.
• 109 Niewiarowski S, Kowalski E. 1958; Un nouvel anticoagulant derive du fibrinogene. Revue d’ Hematologie 13: 320.
• 110 Niewiarowski S, Prou-Wartell O. 1959; Role du facteur contact (facteur Hageman) dans la fibrinolyse. Thrombosis et Diathesis Haemorrhagica 3: 593.
• 111 Niewiarowski S, Regoecz E, Mustard J. F. 1972; Platelet interaction with fibrinogen and fibrin: comparison of the interaction of platelets with that of fibroblasts, leukocytes and erythrocytes. Annals of the New York Academy of Sciences 201: 72.
• 112 Nusbacher J. 1964; Migratory venous thrombosis and cancer. New York State Journal of Medicine 64: 2166.
• 113 Obata I. 1919; On the nature of eclampsia. Journal of Immunology 4: 111.
• 114 Ogston D, Fullerton H. 1961; Changes in fibrinolytic activity produced by physical activity. Lancet II: 730.
• 115 Østerud B, Rapaport S. I, Lavin K. K. 1977; Factor V activity of platelets: evidence for an activated factor V molecule and for a platelet activator. Blood 49: 819.
• 116 Owen Jr. C. A, Bowie E. J. W, Didisheim P, Thompson J. A, Spitell Jr. J. A. 1969. Factor VII and TGA types of hypercoagulabitility. In: Thrombosis. (eds.) Sherry S, Brinkhous K. M, Genton E, Stengle J. M. National Academy of Sciences; Washington, D. C.: 573.
• 117 Page E. W, Fulton L. D, Glendening M. B. 1951; The cause of the blood coagulation defect following abruptio placentae. American Journal of Obstetrics and Gynecology 61: 1116.
• 118 Peterson E. P, Taylor H. B. 1970; Amniotic fluid embolism, an analysis of 40 cases. Obstetrics and Gynecology 35: 787.
• 119 Phillips L. L. 1967; Alterations in the blood clotting system in disseminated intravascular coagulation. American Journal of Cardiology 20: 174.
• 120 Pizzo S. V, Schwartz M. L, Hill R. L, McKee P. A. 1972; Mechanism of Ancrod anticoagulation: A direct proteolytic effect on fibrin. Journal of Clinical Investigation 51: 2841.
• 121 Preston F. E, Malia R. G, Worn M. J, Blackburn E. K. 1973; Intravascular coagulation and E. coli septicemia. Journal of Clinical Pathology 26: 120.
• 122 Quick A. J. 1938; Normal antithrombin of blood and its relation to heparin. American Journal of Physiology 123: 712.
• 123 Quick A. J, Hussey C. V, Harris J, Peters K. 1959; Effect of injecting thrombin intravenously. Federation Proceedings 18: 305.
• 124 Radcliffe R, Bagdasarian R, Colman R. W, Nemerson Y. Activation of factor VII by Hageman factor fragments. Blood. in press.
• 125 Ratnoff O. D. 1966. The biology and pathology of the initial stages of blood coagulation. In: Progress in Hematology. (eds.) Moore C. V, Brown E. Grune and Stratton; New York: 204.
• 126 Ratnoff O. D, Busse R. J, Sheon R. P. 1968; The demise of John Hageman. New England Journal of Medicine 279: 760.
• 127 Ratnoff O. D, Davie E. W, Mallett D. L. 1961; Studies on the action of Hageman factor: evidence that activated Hageman factor in turn activates plasma thromboplastin antecedent. Journal of Clinical Investigation 40: 803.
• 128 Reichle F. A, Stewart G. J. 1973; A transmission and scanning electron microscopic study of luminal surfaces in Dacron and autogenous vein bypass in man and dog. Surgery 74: 945.
• 129 Reid D. E, Weiner A. E, Roby C. C. 1953; Maternal afibrinogenomia associated with long standing intrauterine fetal death. American Journal of Obstetrics and Gynecology 66: 500.
• 130 Revak S. D, Cochrane C. G, Johnston A. R, Hugli T. E. 1974; Structural changes accompanying enzymatic activation of human Hageman factor. Journal of Clinical Investigation 54: 619.
• 131 Rimon A, Shamash Y, Shaprio B. 1966; The plasmin inhibitor of human plasma IV. Its action on plasmin, trypsin, chymotrypsin and thrombin. Journal of Biological Chemistry 241: 5102.
• 132 Ritchie W. G. W, Lynch P. R, Stewart G. J. 1974; The effect of contrast media on normal and inflammed canine venins: A scanning and transmission electron microscopic study. Investigative Radiology 9: 444.
• 133 Robboy S. J, Colman R. W, Minna J. D. 1972; Fibrinolysis versus disseminated intravascular coagulation (DIC): analysis of twenty six cases. Human Pathology 3: 327.
• 134 Robboy S. J, Mihm M. C, Colman R. W, Minna J. D. 1973; The skin in disseminated intravascular coagulation (DIC): prospective analysis of 36 cases. British Journal of Dermatology 88: 221.
• 135 Rodriguez-Erdman F. 1965; Bleeding due to increased intravascular blood coagulation: hemorrhagic syndromes caused by consumption of blood-clotting factors (consumption coagulopathies). New England Journal of Medicine 237: 1370.
• 136 Rosenberg R. D. 1975; Actions and interaction of antithrombin and heparin. New England Journal of Medicine 292: 146.
• 137 Ruckley C. V, Das P. C, Leitch A. G, Donaldson A. A, Copland W. A, Redpath A. T, Scott P, Cash J. D. 1970; Serum fibrin/fibrinogen degradation products associated with postoperative pulmonary embolus and venous thrombosis. British Medical Journal 4: 395.
• 138 Saito H, Ratnoff O. D, Donaldson V. H. 1974; Defective activation of clotting, fibrinolytic and permeability — enhancing systems in human Fletcher trait plasma. Circulation Research 34: 641.
• 139 Saito H, Ratnoff O. D, Waldmann R, Abraham J. P. 1975; Fitzgerald trait: deficiency of a hitherto unrecognized agent, Fitzgerald factor, participating in surface – mediated reactions of clotting, fibrinolysis, generation of kinins and the property of diluted plasma enhancing vascular permeability. Journal of Clinical Investigation 55: 1082.
• 140 Sawyer W. D, Fletcher A. P, Alkjaersig N, Sherry S. 1960; Studies on the thrombolytic activity of human plasma. Journal of Clinical Investigations 39: 426.
• 141 Schiffman S, Lee P. 1974; Preparation, characterization and activation of a highly purified factor XI: Evidence that a hitherto unrecognized plasma activity participates in the interaction of factors XI and XII. British Journal of Haematology 27: 101.
• 142 Schiffman S, Rimon A, Rapaport S. I. 1977; Factor XI and platelets: Evidence thatplatelets contain only minimal factor XI activity and antigen. British Journal of Haematology 35: 429.
• 143 Schneider C. L. 1947; The active principle of placental toxin: thromboplastin; its inactivator in blood: antithromboplastin. American Journal of Physiology 149: 123.
• 144 Schneider C. L. 1951; Fibrin embolism (Disseminated intravascular coagulation) with defibrination as one of the end results of placenta abruption. Surgery, Gynecology and Obstetrics 92: 27.
• 145 Schreiber A. D, Kaplan A. P, Austen K. F. 1973; Inhibition by Cl – INH of Hageman factor fragment activation of coagulation, fibrinolysis and kinin generation. Journal of Clinical Investigation 52: 1402.
• 146 Seegers W. H, Marciniak E. 1962; Inhibition of autoprothrombin C activity with plasma. Nature 193: 1188.
• 147 Seegers W. H, Schneider C. L. 1951. The nature of the blood coagulation mechanism and its relationship to some unsolved problems in obstetrics and gynecology. Fourth International and American Congress on Obstetrics and Gynecology. C. V. Mosby Co.; St. Louis: 469.
• 148 Seegers W. H, Warner E. D, Brinkhous K. M, Smith H. P. 1942; Heparin and antithrombotic activity of plasma. Science 96: 300.
• 149 Sevitt S. 1958; Early and delayed edema and increase in capillary permeability after burns of the skin. Journal of Pathology and Bacteriology 75: 27.
• 150 Sevitt S, Gallagher N. C. 1961; Venous thrombosis and pulmonary embolism: A clinicopathological study in injured and burned patients. British Journal of Surgery 48: 475.
• 151 Sherry S, Fletcher A. P, Alkjaersig N. 1959; Fibrinolysis and fibrinolytic activity in man. Physiology Review 39: 343.
• 152 Shoemaker W. C, Lim L, Boyd D. R, Corley R. S, Reinhard J. M, Dreiling D. A, Kark A. E. 1971; Sequential hemodynamic events after trauma to the unanesthetized patients. Surgery, Gynecology and Obstetrics 132: 651.
• 153 Short A. R. 1914; The nature of surgical Shock. British Journal of Surgery 1: 114.
• 154 Soltay M. J, Movat H. Z, Ozge-Anwar A.H. 1971; The kinin system and human plasma V. The probable derivation of prekallikrein activator from activated Hageman factor (XIIa). Proceedings of the Society for Experimental Biology and Medicine 138: 952.
• 155 Sorkin E, Stecher V. J, Borel J. F. 1970; Chemotaxis of leukocytes and inflammation. Series Haematologica 3: 131.
• 156 Stecher V. J, Sorkin E. 1972; The chemotactic activity of fibrin lysis products. International Archives of Allergy 43: 879.
• 157 Stefanini M, Campbell E. W. 1954; Isolation and purification of platelet thromboplastic factor; its physicochemical and biologic properties in vitro and in vivo. Hematology Review 9: 576.
• 158 Stewart G. J, Lynch P. R. 1977; a Independence of intravascular generation of fibrin monomer and fibrin deposition on canine jugular veins. Thrombosis Research 10: 147.
• 159 Stewart G. J, Lynch P. R, Reichle F. A, Ritchie W. G. M, Smith A, Schaub R. G. 1977; a The adhesion of leukocytes, erythrocytes and noncellular material to the luminal surface of natural and artificial blood vessels in vivo. Annals of New York Academy of Sciences 283: 179.
• 160 Stewart G. J, Ritchie W. G. M, Lynch P. R. 1973. A scanning and transmission electron microscopic study of canine jugular veins. Scanning electron microscopy (Part III). Proceedings of the workshop on Scanning Electron Microscopy in Pathology. ITT Research Institute; Chicago, Ill.: 463.
• 161 Stewart G. J, Ritchie W. G. M, Lynch P. R. 1974; Venous damage produced by massive sticking and emigration of leukocytes. American Journal of Pathology 74: 507.
• 162 Surgenor D. M, Wallach D. F. H. 1961. Biophysical aspects of platelet reaction mechanisms in clotting. (eds.) Johnson S. A. S. N, Monto R. W, Reback J. W, Horn Jr. R. C. In: Blood platelets. Little, Brown and Co.; Boston: 289.
• 163 Thomas D. P, Niewiarowski S, Meyers A. P, Block K. J, Colman R. W. 1970; A comparative study of four methods for detecting fibrinogen degradation products from patients with various disease. New England Journal of Medicine 283: 663.
• 164 Van Creveld S, Paulssen M. M. P. 1953; A form of hemorrhagic diathesis characterized by the lack of the third clotting factor, normally present in blood-platelets (thrombopathia haemophilica). Annals of Paediatrics 181: 193.
• 165 Vecchione J, Zucker M. B. 1975; Procoagulant activity of platelets in recalcified plasma. British Journal of Haematology 31: 423.
• 166 Vennerod A. M, Laake K. 1975; Inhibition of purified plasma kallikrein by antithrombin III and heparin. Thrombosis Research 7: 223.
• 167 Verstraete M, Vermylen L, Vermylen C, Vandenbroucke J. 1965; Excessive consumption of blood coagulation components as cause of hemorrhagic diathesis. American Journal of Medicine 38: 899.
• 168 Virchow R. 1860. Metastatical dyscrasiae. Lecture in Cellular Pathology. Churchill: 196.
• 169 Von Kaulla E, Droegemueller W, Aoki N, von Kaulla K. N. 1971; Antithrombin 3 depression and thrombin generation acceleration in women taking oral contraceptives. American Journal of Obstetrics and Gynecology 109: 868.
• 170 Walsh P. N. 1972; a The role of platelets in the contact phase of blood coagulation. British Journal of Haematology 22: 237.
• 171 Walsh P. N. 1972; b The effects of collagen and kaolin on the intrinsic coagulant activity of platelets. Evidence for an alternative pathway in intrinsic coagulation not requirin factor XII. British Journal of Haematology 22: 393.
• 172 Walsh P. N, Lipscomb M. S. 1976; Comparison of the coagulant activities of platelets and phospholipids. British Journal of Haematology 33: 9.
• 173 Walsh P. N, Rogers P. H, Marder V. J, Gagnatelli G, Escovitz E. S, Sherry S. 1976; The relationship of platelet coagulant activities to venous thrombosis following hip surgery. British Journal of Haematology 32: 423.
• 174 Ward P. A. 1967; A plasmin-split fragment of C3 as a new chemotactic factor. Journal of Experimental Medicine 126: 189.
• 175 Weiss A. S, Gallin J. I, Kaplan A. P. 1974; Fletcher factor deficiency. A diminshed rate of Hageman factor activation caused by absence of prekallikrein with abnomalities of coagulation, fibrinolysis, chemotactic activity and kinin generation. Journal of Clinical Investigation 53: 622.
• 176 Wessler S. 1952; Studies in intravascular coagulation. I. Coagulation changes in isolated venous segments. Journal of Clinical Investigation 31: 1011.
• 177 Wessler R. 1955; Studies in intravascular coagulation. III. The pathogenesis of serum-induced venous thrombosis. Journal of Clinical Investigation 34: 647.
• 178 Wessler S, Reimer L, Freiman D. G, Reimer S. M, Lortzman M. 1959; Serum-induced thrombosis. Studies of its introduction and evolution under controlled conditions in vivo. Circulation 20: 864.
• 179 Wessler S, Yin E. T. 1968; The experimental hypercoagulable state induced by Factor X: comparison of the non-activated and activated forms. Journal of Laboratory Clinical Medicine 72: 256.
• 180 Wilner G. D, Nossel H. L, Leroy E. C. 1968; Activation of Hageman factor by collagen. Journal of Clinical Investigation 47: 2608.
• 181 Wood E. H, Prentice C. R. M, McNicol G. P. 1972; Association of fibrinogen-fibrin related antigen (F. R.-antigen) with postoperative deep vein thrombosis and systemic complication. Lancet I: 166.
• 182 Wuepper K. D. 1972. Biochemistry and biology of components of the plasmin kinin system. In: Inflammation, Mechanism and Control. (eds.) Lepow I. H, Ward P. A. Academic Press; New York: 93.
• 183 Wuepper K. D, Miller D. R, Lacombe M. J. 1975; Flaujeac trait. Deficiency of human plasma kininogen. Journal of Clinical Investigation 56: 1663.
• 184 Yin T. E, Wessler S, Stoll P. J. 1971; Identity of plasma-activated factor X inhibitor with antithrombin III and heparin cofactor. Journal of Biology and Chemistry 246: 3712.
• 185 Zachariae H, Malmquest J, Oates J. A, Pettinger W. 1976; Studies on the mechanism of kinin formation in inflammation. Journal of Physiology 190: 81.
• 186 Zuck T. F, Bergin J. J. 1973; Thrombotic predispostion associated with oral contraceptives. Obstetrics and Gynecology 41: 427.
• 187 Zuck T. F, Bergin J. J, Raymond J. M. 1971; Implications of depressed antithrombin III activity associated with oral contraceptives. Surgery, Gynecology and Obstetrics 133: 609.